Profile | GDS2987 / GI_16357500-A |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 43 | 69 |
GSM215244 | HMVEC_vehicle_rep2 | 29.2 | 57 |
GSM215253 | HMVEC_vehicle_rep3 | 43.1 | 69 |
GSM215254 | HMVEC_atorvastatin_rep1 | 111 | 77 |
GSM215282 | HMVEC_atorvastatin_rep3 | 114.3 | 77 |
GSM215344 | HMVEC_atorvastatin_rep2 | 83.4 | 74 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 45.8 | 63 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 29.5 | 50 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 25.8 | 39 |
GSM215294 | HMVEC_SLx2119_rep1 | 47.3 | 70 |
GSM215295 | HMVEC_SLx2119_rep2 | 26.3 | 47 |
GSM215296 | HMVEC_SLx2119_rep3 | 23.8 | 38 |
GSM215297 | PASMC_vehicle_rep1 | ||
GSM215298 | PASMC_vehicle_rep2 | 13.4 | 21 |
GSM215310 | PASMC_vehicle_rep3 | 15.8 | 25 |
GSM215311 | PASMC_atorvastatin_rep1 | ||
GSM215312 | PASMC_atorvastatin_rep2 | 11 | 18 |
GSM215313 | PASMC_atorvastatin_rep3 | 24.7 | 35 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 13.2 | 22 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | ||
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | ||
GSM215327 | PASMC_SLx2119_rep1 | 6.5 | 12 |
GSM215328 | PASMC_SLx2119_rep2 | 44.7 | 60 |
GSM215329 | PASMC_SLx2119_rep3 | 10.8 | 21 |
GSM215330 | Fibroblasts_vehicle_rep1 | 0.5 | 1 |
GSM215331 | Fibroblasts_vehicle_rep2 | ||
GSM215332 | Fibroblasts_vehicle_rep3 | 7.3 | 25 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | ||
GSM215334 | Fibroblasts_atorvastatin_rep2 | ||
GSM215335 | Fibroblasts_atorvastatin_rep3 | ||
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | ||
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | ||
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | ||
GSM215339 | Fibroblasts_SLx2119_rep1 | ||
GSM215340 | Fibroblasts_SLx2119_rep2 | ||
GSM215341 | Fibroblasts_SLx2119_rep3 |